Algeta expands clinical programme for radiopharmaceutical

Algeta ASA is expanding the clinical development programme for its radiopharmaceutical, Alpharadin (radium 223 chloride), to see if the product can be used for bone metastases from breast cancer as well as those from prostate cancer.